CorMedix is a bio-pharmaceutical company that produces DefenCath, an antimicrobial catheter lock solution containing ...

The duration of therapy for CRBSI depends on whether the CVC is removed and the isolated organism (s). If the CVC is removed, patients should receive 7 to 14 days of appropriate antibiotics.

CRBSI can be diagnosed when colony counts are at least 3-fold higher in cultures of blood obtained via the CVC than in cultures of blood taken from a peripheral vein. [6] ...

Catheter-related bloodstream infection (CRBSI) or central line-associated bloodstream infections (CLABSIs) are associated with increased morbidity, mortality and healthcare costs. 1 The epidemiology ...

The global CRBSI Treatment Market is projected to be valued at USD 1,718.0 Million in 2025 and is expected to reach USD 2,908 Million by 2035, registering a CAGR of 5.4% during the forecast period, ...